Drug Development

This paper provides an in-depth overview of the anatomical structure and functional dynamics of renal filtration, secretion, and reabsorption processes that govern drug clearance.

US President Donald Trump made the announcement that AstraZeneca is the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.

AstraZeneca’s $4.5 billion investment in Virginia expands its US drug manufacturing footprint, creating 3600 jobs and integrating AI for cancer and metabolic therapies.

The awarded $1.7 million in funding will support the company’s preclinical and clinical progress on DMX-1001 (noribogaine), designed to reduce relapse and improve brain health in patients with alcohol use disorder.

The growing demand for liquid medicines is increasingly driven by the unique needs of several distinct patient groups, improving compliance in these demographics through flexible, palatable dosing options.

The licensing of Talicia, an FDA-approved fixed-dose therapy, to key at-risk markets strategically combats an increasingly high antibiotic resistance to the cancer-causing bacteria.

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.

Artificial intelligence and machine learning are anticipated to boost success rates.

Artificial intelligence, machine learning, and novel instruments are helping drug developers evaluate complex data from bioanalytical studies.

Siegfried Schmitt, PhD, vice-president, Technical at Parexel, answers questions on the use and benefits of real-world evidence for small-molecule and large-molecule drug development.

This article takes a look at the developing use of AI in pharmaceutical development and manufacturing.

The go-ahead for Novartis’ oral treatment marks a new option for patients with spontaneous urticaria who remain symptomatic despite antihistamine therapy.

Sept. 30 marked 61 days since July 31, one day past the timeframe President Donald Trump had set forth for companies to lower prescription drug prices in the United States.

A draft reflection paper on patient experience data is up for public consultation until Jan. 31, 2026.

Vienna to host BIO-Europe 2025, connecting top biopharma companies for collaborations and pipeline development.

The dispute shines a light on the vulnerability of long-established drugs to renewed safety scrutiny: Even when causal evidence is lacking, observational findings can influence policy and public perception.

Pfizer gains access to Metsera’s oral and injectable obesity candidates, underscoring innovation in drug development and scalable manufacturing.

EMA states the new variations guidelines will streamline lifecycle management and make processing variations quicker.

CDC panel shifts vaccine policy by discouraging combined MMRV shot for young children due to increased febrile seizure risk.

The Phase IIa study will test HTL0039732 in combination with immunotherapy to boost responses in resistant solid tumors and broaden treatment choices.

Corstasis Therapeutics plans to launch the product in the United States in the fourth quarter of 2025.

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated steatohepatitis arena.

The 2024 edition of the annual conference, held in Milan, attracted more than 59,000 professionals from across the bio/pharmaceutical landscape.

The two organizations are collaborating on an integrated translational biology platform for the development of radiopharmaceuticals.

Scientific discovery, technological evolution, and market demands are constantly reshaping the landscape.

Bothe data integrity and quality of data are critical for drug discovery, manufacturing efficiency, regulatory compliance, and patient safety.

The partnership, which has received £118 million (US$158 million) in research funding, aims to establish a better understanding not only of how the body fights infection, but also how vaccines protect it.

This article previews some formulation topics discussed in the Pharma Fundamentals series, which aims to enhance learning for professionals in pharmaceutical drug development and manufacturing.

Aficamten is a small-molecule cardiac myosin inhibitor that was compared for the first time in the trial to the standard-of-care beta blocker.

EMA and WHO have collaborated for a decade, with WHO utilizing EMA’s scientific expertise to fulfill its mandate to improve access to safe and effective medicines.